Close menu




Innovations

Photo credits: pixabay.com

Commented by Armin Schulz on May 6th, 2024 | 07:15 CEST

Bayer on the path out of crisis. With their oncology pipelines, are Defence Therapeutics and BioNTech also on the verge of a turnaround?

  • Biotechnology
  • Pharma
  • Cancer
  • Innovations

After several years of stumbling from one crisis to another, pharmaceutical and agrochemical giant Bayer is now showing signs of a recovery on the horizon. As Bayer navigates its long and rocky road out of the crisis, investors and industry experts are now turning their attention to two other exciting biotech companies: Defence Therapeutics and BioNTech. Both companies, which have caused a sensation in the past mainly due to their revolutionary approaches in cancer therapy, could follow in Bayer's footsteps with their promising oncology pipelines, moving from uncertainty to a bright future.

Read

Commented by André Will-Laudien on April 24th, 2024 | 07:00 CEST

Takeover rumors for biotech shares: BioNTech, Formycon, Cardiol Therapeutics and Novo Nordisk in focus

  • Biotechnology
  • Pharma
  • Innovations
  • Cancer

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is due to high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany's economic conditions are deteriorating dramatically, particularly due to the ongoing geopolitical conflicts. It should, therefore, come as no surprise if the ECB announces an "emergency interest rate cut" in the summer. That would then be the starting signal for a major reshuffle out of the best performers of recent months and into the long-neglected biotech segment. We have selected a few interesting stocks.

Read

Commented by Fabian Lorenz on April 23rd, 2024 | 07:00 CEST

TAKEOVER FEVER for biotech shares! Evotec, Bayer, Vidac Pharma - Who will follow Morphosys?

  • Biotechnology
  • Pharma
  • Innovations
  • Cancer

There is takeover fever in the biotech sector. Genmab recently announced the acquisition of ProfoundBio, the US biotech company developing ovarian and endometrial cancer drugs, for USD 1.8 billion. With Morphosys, the takeover carousel is also turning in Germany. Who is the next candidate? Evotec is often mentioned. Due to unauthorized insider trading, the biotech company's shares have come under fire this year and offer an interesting entry opportunity. Vidac Pharma also impresses operationally. The Company's new approach has the potential to revolutionize cancer treatment. The study results of the past few months are very promising. Bayer shares surprised investors yesterday as one of the day's winners in the DAX. Is the Leverkusen-based company's stock about to take off?

Read

Commented by Juliane Zielonka on April 18th, 2024 | 07:00 CEST

Volkswagen, Altech Advanced Materials, BYD - who can benefit from China's rise

  • Innovations
  • Technology
  • Electromobility
  • Batteries

Chinese companies such as BYD benefit from state subsidies and domestic access to raw materials. BYD's subsidies have risen from EUR 220 million in just three years to EUR 2.1 billion. These sums are helping BYD dominate the Chinese electric vehicle market and increasingly penetrate the European market. Volkswagen cannot escape the pull of China either. As part of its "In China, for China" strategy, Volkswagen is expanding its cooperation network with Chinese partners. The aim is to reduce costs significantly in the development of EV technology. For companies like Altech Advanced Materials, close cooperation with Chinese market leaders such as BYD and Volkswagen offers the opportunity to commercialize innovative battery technologies that meet the needs of the changing market. One of these innovations, made in Germany by Altech Advanced Materials, increases the longevity of EV batteries by 30%. Here are the details.

Read

Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

  • Pharma
  • Biotechnology
  • Innovations

Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.

Read

Commented by Armin Schulz on April 2nd, 2024 | 06:45 CEST

MorphoSys, Defence Therapeutics, Novo Nordisk - Biotech deals: Corporations on a shopping spree!

  • Pharma
  • Biotechnology
  • Innovations
  • Technology

In 2023, the volume of business in the pharmaceutical industry, with mergers and acquisitions, reached USD 152 billion despite high interest rates. Experts predict that this momentum could continue as large pharmaceutical companies are facing a wave of patent expiries for their key products that will roll in between 2025 and 2030. Companies are therefore on the lookout for new active ingredients, often by acquiring or licensing developments from smaller biotech companies to compensate for potential revenue shortfalls. There have also been major takeovers in recent months. We take a look at takeover targets and buyers.

Read

Commented by André Will-Laudien on March 19th, 2024 | 06:30 CET

Pay attention now - 100% performance possible with BioNTech, Bayer, Cardiol Therapeutics or HelloFresh

  • Biotechnology
  • Pharma
  • Innovations
  • Food

For investors in the biotech sector, 2024 is starting much like the previous year ended. Everyone is waiting for the big bang, which has yet to materialize. However, now that there is no longer a pandemic and cancer research is still stuck in a rut, selection has become crucial. Investing only in the future is no longer a guarantee of profit; instead, it is much more important to identify the most innovative business models and follow them. BioNTech does not currently have a blockbuster but has a good EUR 17 billion in its coffers. Bayer has seen its share price drop fivefold since 2019, and HelloFresh is also unable to keep its promises. By contrast, Cardiol Therapeutics has experienced a true rally. What lies next here?

Read

Commented by Juliane Zielonka on March 15th, 2024 | 06:00 CET

Altech Advanced Materials, Tesla, E.ON - Accelerators of the Future in Europe

  • Innovations
  • Technology
  • Batteries
  • renewableenergies
  • Electromobility

Germany's automotive industry is in a state of upheaval. With an annual turnover of EUR 411 billion, solutions are urgently needed to drive electrification forward. E.ON, as one of the largest utilities, is investing billions in European infrastructure for this purpose. The Company is also increasing its dividend. Heidelberg-based Altech Advanced Materials is launching stationary battery storage systems on the market at the beginning of April. It has also published the results of the current feasibility study for its second pillar: a special coating for silicon battery anodes that ensures greater power and longevity. These are exactly the sticking points that customers have been complaining about so far. Tesla also relies on silicon batteries in its models. This week, Elon Musk visited the German plant in Grünheide, and has some good news in store...

Read

Commented by Stefan Feulner on March 11th, 2024 | 06:30 CET

Novo Nordisk, Defence Therapeutics, Bayer - Rally after the breakout?

  • Biotechnology
  • Pharma
  • Innovations

Biotechnology has been revived after a disappointing stock market year in 2023. In addition to the interest rate cut fantasy, which should benefit the capital-intensive and innovative sector in particular, the current wave of acquisitions should lead to further price rises. Although the broad Nasdaq Biotech Index has only risen by 3% since the beginning of the year, it is currently facing key resistance levels. If these are broken through, the momentum northwards could accelerate.

Read

Commented by Armin Schulz on February 28th, 2024 | 07:15 CET

Varta Thriller! Altech Advanced Materials, BYD work on the electrification of the future

  • Technology
  • Innovations
  • renewableenergies

While production at Varta is at a standstill following a cyber attack, the wave of electrification is rolling inexorably through our society, changing how we generate, store and utilize energy. Innovations are needed here, especially in energy storage from renewable sources and the further development of batteries for use in electric vehicles. Advances in electric vehicles and the increasing use of electrical energy are paving the way towards the future. Intensive research is currently being carried out on technologies that will increase both the effectiveness and capacity of battery systems. Altech Advanced Materials and BYD stand out here.

Read